Lisata Therapeutics, Inc. (NASDAQ:LSTA) Q2 2023 Results Conference Call August 15, 2023 8:30 AM ET
Company Participants
John Menditto - VP, IR and Corporate Communications
Dr. David Mazzo - President and Chief Executive Officer
Dr. Kristen Buck - EVP, Research and Development and Chief Medical Officer
James Nisco - VP, Finance and Treasury
Conference Call Participants
Steve Brozak - WBB Securities
Pete Enderlin - MAZ Partners
Kemp Dolliver - Brookline Capital Markets
Operator
Welcome to the Lisata Therapeutics Second Quarter 2023 Financial Results and Business Update Conference Call. Currently, all participants are in a listen-only mode. Following managements' prepared remarks, we will hold a question-and-answer session. [Operator Instructions] As a reminder, the call is being recorded today, Tuesday, August 15, 2023.
I will now turn the call over to John Menditto, Vice President of Investor Relations and Corporate Communications at Lisata. Please go ahead, sir.
John Menditto
Thank you, operator, and good morning, everyone. Welcome to Lisata's Second Quarter 2023 Conference Call to discuss our financial results and the opportunity to provide a business update. Joining me today from our management team are Dr. David Mazzo, President and Chief Executive Officer; Dr. Kristen Buck, Executive Vice President of Research & Development and Chief Medical Officer; and James Nisco, Vice President of Finance and Treasury.
Yesterday, Monday, August 14, we issued a press release aftermarket trading closed announcing our second quarter 2023 financial results, which is available under the Investors and News section of the Company website along with the webcast replay of this call. If you have not received the news release or if you'd like to be added to the Company's e-mail distribution list, please e-mail me at jmenditto@lisata.com.
Before we begin, I remind you that comments made by management during this conference call will contain forward-looking statements that involve risks and uncertainties regarding the operations and future results of Lisata. I encourage you to review the Company's filings with the Securities and Exchange Commission, including, without limitation, its forms 10-Q, 8-K and 10-K, which identify specific risk factors that may cause actual results or events to differ materially from those described in the forward-looking statements. Furthermore, the content of this conference call contains time-sensitive information that is accurate only as of the date of this live broadcast, Tuesday, August 15, 2023.
Lisata undertakes no obligation to revise or update any statements to reflect events or circumstances after the date of this conference call.